MAP2K1 and melanoma: In 2012, Nikolaev et al. performed exome sequencing to detect somatic mutations in melanoma and found the presence of somatic mutations in MAP2K1/MAP2K2, downstream effectors of the RAS-RAF-MEK pathway, with an overall frequency of 8%.